More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis

scientific article published on 24 September 2020

More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3350/CMH.2020.0228
P932PMC publication ID7641542
P698PubMed publication ID32967407

P2093author name stringPaul Kwo
Deepti Dronamraju
P2860cites workAn integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infectionQ92319689
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysisQ92720274
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label studyQ96342937
Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairmentQ98776756
The Current State of Peritoneal DialysisQ30243902
Hepatitis C virus itself is a causal risk factor for chronic kidney disease beyond traditional risk factors: a 6-year nationwide cohort study across TaiwanQ34980383
Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?Q38032025
Hepatitis C Virus Infection Increases the Risk of Developing Chronic Kidney Disease: A Systematic Review and Meta-AnalysisQ38551250
Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality in Patients with Advanced Liver DiseaseQ40117313
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 studyQ40957442
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.Q41918943
Hepatitis C infection is very rarely treated among hemodialysis patients.Q42257638
Direct-Acting Antiviral Sustained Virologic Response: Impact on Mortality in Patients without Advanced Liver DiseaseQ47644014
P275copyright licenseCreative Commons Attribution-NonCommercial 3.0 UnportedQ18810331
P6216copyright statuscopyrightedQ50423863
P921main subjectchronic renal insufficiencyQ736715
peritoneal dialysisQ1756474
P577publication date2020-09-24
P1433published inClinical and molecular hepatologyQ26853927
P1476titleMore evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis

Search more.